Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Jun;29(6):749–758. doi: 10.1111/j.1365-2125.1990.tb03697.x

Haemodynamic dose-response effects of UK-52,046 in ischaemic disease with or without impaired left ventricular function.

B Silke 1, A V Zezulka 1, S P Verma 1, T C Tham 1, S H Taylor 1
PMCID: PMC1380178  PMID: 1974144

Abstract

1. The haemodynamic effects of a new cardioselective postsynaptic alpha 1-adrenoceptor antagonist UK-52,046, were evaluated in 25 patients with stable coronary disease, with or without impaired left ventricular function. At rest the haemodynamic effects to two dose-response regimens were determined. In an initial eight patients 0.125, 0.125 and 0.25 micrograms kg-1 were administered peripherally at 15 min intervals; the haemodynamic measurements were determined between 10 to 15 min after each dose. In a further 17 patients, the dose regimen was doubled yielding a cumulative dose-regimen of 0.25, 0.5 and 1.0 micrograms kg-1. The exercise effects were determined by comparison of measurements during 4 min of supine sub-maximal bicycle exercise at a fixed workload before and after drug treatment. 2. At rest, the lower dose regimen of UK-52,046 significantly reduced systemic mean arterial blood pressure (-5 mm Hg; P less than 0.05) and increased cardiac index (+0.2 l min-1 m-2, P less than 0.01). The higher dose regimen of UK-52,046 reduced systemic mean arterial blood pressure (-7 mm Hg; P less than 0.01), pulmonary artery occluded pressure (PAOP) (-2 mm Hg, P less than 0.01) and vascular resistance index (-314 dyn s cm-5 m2; P less than 0.05) with an increase in heart rate (+7%, P less than 0.05) and cardiac index (+0.2 l min-1 m-2, P less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
749

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnold S. B., Williams R. L., Ports T. A., Baughman R. A., Benet L. Z., Parmley W. W., Chatterjee K. Attenuation of prazosin effect on cardiac output in chronic heart failure. Ann Intern Med. 1979 Sep;91(3):345–349. doi: 10.7326/0003-4819-91-3-345. [DOI] [PubMed] [Google Scholar]
  2. Aronow W. S., Danahy D. T. Efficacy of trimazosin and prazosin therapy on cardiac and exercise performance in outpatients with chronic congestive heart failure. Am J Med. 1978 Jul;65(1):155–160. doi: 10.1016/0002-9343(78)90704-0. [DOI] [PubMed] [Google Scholar]
  3. Aronow W. S., Lurie M., Turbow M., Whittaker K., Van Camp S., Hughes D. Effect of prazosin vs placebo on chronic left ventricular heart failure. Circulation. 1979 Feb;59(2):344–350. doi: 10.1161/01.cir.59.2.344. [DOI] [PubMed] [Google Scholar]
  4. Awan N. A., Miller R. R., DeMaria A. N., Maxwell K. S., Neumann A., Mason D. T. Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodynamics and echocardiography. Circulation. 1977 Sep;56(3):346–354. doi: 10.1161/01.cir.56.3.346. [DOI] [PubMed] [Google Scholar]
  5. Brückner R., Mügge A., Scholz H. Existence and functional role of alpha 1-adrenoceptors in the mammalian heart. J Mol Cell Cardiol. 1985 Jul;17(7):639–645. doi: 10.1016/s0022-2828(85)80063-8. [DOI] [PubMed] [Google Scholar]
  6. De Kock M. R., Detry J. M. Acute effects of intravenous indoramin on the hemodynamic adaptation at rest and during exercise in chronic congestive heart failure. J Cardiovasc Pharmacol. 1986;8 (Suppl 2):S107–S111. doi: 10.1097/00005344-198600082-00023. [DOI] [PubMed] [Google Scholar]
  7. Flores N. A., Sheridan D. J. Electrophysiological and antiarrhythmic effects of UK 52,046-27 during ischaemia and reperfusion in the guinea-pig heart. Br J Pharmacol. 1989 Mar;96(3):670–674. doi: 10.1111/j.1476-5381.1989.tb11867.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Forrester J. S., Ganz W., Diamond G., McHugh T., Chonette D. W., Swan H. J. Thermodilution cardiac output determination with a single flow-directed catheter. Am Heart J. 1972 Mar;83(3):306–311. doi: 10.1016/0002-8703(72)90429-2. [DOI] [PubMed] [Google Scholar]
  9. Hoel B. L. Some aspects of the clinical use of thermodilution in measuring cardiac output. With particular reference to the Swan-Ganz thermodilution catheters. Scand J Clin Lab Invest. 1978 Jun;38(4):383–388. doi: 10.3109/00365517809108438. [DOI] [PubMed] [Google Scholar]
  10. Packer M., Medina N., Yushak M. Comparative hemodynamic and clinical effects of long-term treatment with prazosin and captopril for severe chronic congestive heart failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol. 1986 Jun 1;57(15):1323–1327. doi: 10.1016/0002-9149(86)90212-2. [DOI] [PubMed] [Google Scholar]
  11. Packer M., Meller J., Gorlin R., Herman M. V. Hemodynamic and clinical tachyphylaxis to prazosin-mediated afterload reduction in severe chronic congestive heart failure. Circulation. 1979 Mar;59(3):531–539. doi: 10.1161/01.cir.59.3.531. [DOI] [PubMed] [Google Scholar]
  12. Rubin S. A., Chatterjee K., Gelberg H. J., Ports T. A., Brundage B. H., Parmley W. W. Paradox of improved exercise but not resting hemodynamics with short-term prazosin in chronic heart failure. Am J Cardiol. 1979 Apr;43(4):810–815. doi: 10.1016/0002-9149(79)90082-1. [DOI] [PubMed] [Google Scholar]
  13. Sheridan D. J., Penkoske P. A., Sobel B. E., Corr P. B. Alpha adrenergic contributions to dysrhythmia during myocardial ischemia and reperfusion in cats. J Clin Invest. 1980 Jan;65(1):161–171. doi: 10.1172/JCI109647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Silke B., Hendry W. G., Taylor S. H. Immediate and sustained haemodynamic effects of prazosin during upright exercise in man. Br Heart J. 1981 Dec;46(6):663–670. doi: 10.1136/hrt.46.6.663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Silke B., Lakhani Z. M., Taylor S. H. Pharmacokinetic and pharmacodynamic studies with prazosin in chronic heart failure. J Cardiovasc Pharmacol. 1981 Mar-Apr;3(2):329–335. doi: 10.1097/00005344-198103000-00011. [DOI] [PubMed] [Google Scholar]
  16. Silke B., Nelson G. I., Verma S. P., Frais M. A., Reynolds G., Jackson N., Taylor S. H. Haemodynamic dose-response effects of intravenous indoramin in acute heart failure complicating myocardial infarction. J Cardiovasc Pharmacol. 1986;8 (Suppl 2):S102–S106. doi: 10.1097/00005344-198600082-00022. [DOI] [PubMed] [Google Scholar]
  17. Silke B., Nelson G. I., Verma S. P., Hussain M., Ahuja R. C., Walker C., Taylor S. H. Enhanced haemodynamic effects of propranolol in acute myocardial infarction. Eur Heart J. 1984 May;5(5):366–373. doi: 10.1093/oxfordjournals.eurheartj.a061670. [DOI] [PubMed] [Google Scholar]
  18. Singleton W., Saxton C. A., Hernandez J., Prichard B. N. Postjunctional selectivity of alpha-blockade with prazosin, trimazosin, and UK-33,274 in man. J Cardiovasc Pharmacol. 1982;4 (Suppl 1):S145–S151. doi: 10.1097/00005344-198200041-00029. [DOI] [PubMed] [Google Scholar]
  19. Sorensen M. B., Bille-Brahe N. E., Engell H. C. Cardiac output measurement by thermal dilution: reproducibility and comparison with the dye-dilution technique. Ann Surg. 1976 Jan;183(1):67–72. doi: 10.1097/00000658-197601000-00014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Taylor S. H., Silke B., Nelson G. I. Principles of treatment of left ventricular failure. Eur Heart J. 1982 Dec;3 (Suppl 500):19–43. [PubMed] [Google Scholar]
  21. Uprichard A. G., Harron D. W., Wilson R., Shanks R. G. Effects of the myocardial-selective alpha 1-adrenoceptor antagonist UK-52046 and atenolol, alone and in combination, on experimental cardiac arrhythmias in dogs. Br J Pharmacol. 1988 Dec;95(4):1241–1254. doi: 10.1111/j.1476-5381.1988.tb11761.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Verma S. P., Silke B., Hussain M., Nelson G. I., Wilson J. A., Reynolds G. W., Richmond A., Taylor S. H. Sympathetic (alpha-beta) or calcium channel blockade for hypertensive myocardial infarction? A haemodynamic comparison of labetalol and nifedipine. J Hypertens. 1988 Nov;6(11):897–904. doi: 10.1097/00004872-198811000-00008. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES